Zeltia SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Zeltia SA's GENOMICA SAU Establishes Subsidiary
Zeltia SA announced that its subsidiary GENOMICA SAU goes a step further in its internationalization process by establishing, as of January 17, 2013, new Scandinavian subsidiary GENOMICA AB. Based in Lund (Sweden), GENOMICA AB intends to support the Scandinavian market (Denmark, Sweden and Norway), due to its strategic importance and also for its high growth potential.
Latest Developments for Zeltia SA
Latest Key Developments in Biotechnology
- Dyax Corp receives orphan drug designation from the U.S. FDA for DX-2930 in hereditary angioedema
- Genmab to be included in OMXC20CAP and OMXC20 indexes-Reuters
- Immunicum AB announces positive results for cancer vaccine INTUVAX in treatment of kidney cancer
- Zealand Pharma says data presented by Sanofi support flexibility in timing of administration for Lyxumia
- Share this
- Digg this